1
|
Debas K, Carrier J, Barakat M, Marrelec G, Bellec P, Hadj Tahar A, Karni A, Ungerleider LG, Benali H, Doyon J. Off-line consolidation of motor sequence learning results in greater integration within a cortico-striatal functional network. Neuroimage 2014; 99:50-8. [PMID: 24844748 DOI: 10.1016/j.neuroimage.2014.05.022] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2013] [Revised: 04/28/2014] [Accepted: 05/10/2014] [Indexed: 10/25/2022] Open
Abstract
The consolidation of motor sequence learning is known to depend on sleep. Work in our laboratory and others have shown that the striatum is associated with this off-line consolidation process. In this study, we aimed to quantify the sleep-dependent dynamic changes occurring at the network level using a measure of functional integration. We directly compared changes in connectivity before and after sleep or the simple passage of daytime. As predicted, the results revealed greater integration within the cortico-striatal network after sleep, but not an equivalent daytime period. Importantly, a similar pattern of results was also observed using a data-driven approach; the increase in integration being specific to a cortico-striatal network, but not to other known functional networks. These findings reveal, for the first time, a new signature of motor sequence consolidation: a greater between-regions interaction within the cortico-striatal system.
Collapse
Affiliation(s)
- Karen Debas
- Functional Neuroimaging Unit, Centre de recherche de l'institut gériatrique de l'université de Montréal, Québec, Canada; Department of Psychology, University of Montreal, Québec, Canada
| | - Julie Carrier
- Functional Neuroimaging Unit, Centre de recherche de l'institut gériatrique de l'université de Montréal, Québec, Canada; Centre d'étude du sommeil et des rythmes biologiques, Hôpital du Sacré-Cœur de Montréal, Québec, Canada; Department of Psychology, University of Montreal, Québec, Canada
| | - Marc Barakat
- Functional Neuroimaging Unit, Centre de recherche de l'institut gériatrique de l'université de Montréal, Québec, Canada; Department of Psychology, University of Montreal, Québec, Canada
| | - Guillaume Marrelec
- Functional Neuroimaging Unit, Centre de recherche de l'institut gériatrique de l'université de Montréal, Québec, Canada; Unité Mixte de Recherche-S 678, INSERM/University, Paris VI, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France
| | - Pierre Bellec
- Functional Neuroimaging Unit, Centre de recherche de l'institut gériatrique de l'université de Montréal, Québec, Canada
| | - Abdallah Hadj Tahar
- Functional Neuroimaging Unit, Centre de recherche de l'institut gériatrique de l'université de Montréal, Québec, Canada
| | - Avi Karni
- Laboratory for Functional Brain Imaging and Learning Research, The Brain-Behavior Center, University of Haifa, Haifa, Israel
| | | | - Habib Benali
- Unité Mixte de Recherche-S 678, INSERM/University, Paris VI, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France
| | - Julien Doyon
- Functional Neuroimaging Unit, Centre de recherche de l'institut gériatrique de l'université de Montréal, Québec, Canada; Department of Psychology, University of Montreal, Québec, Canada; Unité Mixte de Recherche-S 678, INSERM/University, Paris VI, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France.
| |
Collapse
|
2
|
Hadj Tahar A, Chuang R, Steeves T, Jog M, Lang A, Grimes D. Efficacy and safety of T2000 in older patients with essential tremor. Parkinsonism Relat Disord 2012; 19:485-6. [PMID: 23254160 DOI: 10.1016/j.parkreldis.2012.11.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/27/2012] [Revised: 11/08/2012] [Accepted: 11/12/2012] [Indexed: 11/30/2022]
|
3
|
Morissette M, Samadi P, Hadj Tahar A, Bélanger N, Di Paolo T. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:446-54. [PMID: 20026151 DOI: 10.1016/j.pnpbp.2009.12.011] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/04/2009] [Revised: 11/19/2009] [Accepted: 12/13/2009] [Indexed: 01/26/2023]
Abstract
L-Dopa treatment, the gold standard therapy for Parkinson's disease, is hampered by motor complications such as dyskinesias. Recently, impairment of striatal Akt/GSK3 signaling was proposed to play a role in the mechanisms implicated in development of L-Dopa-induced dyskinesias in a rodent model of Parkinson's disease. The present experiment investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys, the effects on Akt/GSK3 of chronic L-Dopa treatment inducing dyskinesias compared to L-Dopa with CI-1041 (NMDA receptor antagonist) or a low dose of cabergoline (dopamine D2 receptor agonist) preventing dyskinesias. The extensive dopamine denervation induced by MPTP was associated with a decrease by about half of phosphorylated Akt(Ser473) levels in posterior caudate nucleus, anterior and posterior putamen; smaller changes were observed for phosphorylated Akt(Thr308) levels that did not reach statistical significance. Dopamine depletion reduced phosphorylated GSK3beta(Ser9) levels, mainly in posterior putamen whereas pGSK3beta(Tyr216) and pGSK3alpha(Ser21) were unchanged. In posterior caudate nucleus, anterior and posterior putamen of dyskinetic L-Dopa-treated MPTP monkeys, pAkt(Ser473) and pGSK3beta(Ser9) were elevated whereas L-Dopa+cabergoline treated MPTP monkeys without dyskinesias had lower values in posterior striatum as vehicle-treated MPTP monkeys. In non-dyskinetic MPTP monkeys treated with L-Dopa+CI-1041, putamen pAkt(Ser473) and pGSK3beta(Ser9) levels remained elevated as in dyskinetic monkeys while in posterior caudate nucleus, these levels were low as vehicle-treated and lower than L-Dopa treated MPTP monkeys. Extent of phosphorylation of Akt and GSK3beta in putamen correlated positively with dyskinesias scores of MPTP monkeys; these correlations were higher with dopaminergic drugs (L-Dopa, cabergoline) suggesting implication of additional mechanisms and/or signaling molecules in the NMDA antagonist antidyskinetic effect. In conclusion, our results showed that in MPTP monkeys, loss of striatal dopamine decreased Akt/GSK3 signaling and that increased phosphorylation of Akt and GSK3beta was associated with L-Dopa-induced dyskinesias.
Collapse
Affiliation(s)
- Marc Morissette
- Molecular Endocrinology and Genomic Research Centre, CHUQ, Laval University Medical Centre, Quebec, Canada
| | | | | | | | | |
Collapse
|
4
|
Doyon J, Korman M, Morin A, Dostie V, Hadj Tahar A, Benali H, Karni A, Ungerleider LG, Carrier J. Contribution of night and day sleep vs. simple passage of time to the consolidation of motor sequence and visuomotor adaptation learning. Exp Brain Res 2009; 195:15-26. [PMID: 19277618 PMCID: PMC2752878 DOI: 10.1007/s00221-009-1748-y] [Citation(s) in RCA: 173] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2008] [Accepted: 02/16/2009] [Indexed: 10/21/2022]
Abstract
There is increasing evidence supporting the notion that the contribution of sleep to consolidation of motor skills depends on the nature of the task used in practice. We compared the role of three post-training conditions in the expression of delayed gains on two different motor skill learning tasks: finger tapping sequence learning (FTSL) and visuomotor adaptation (VMA). Subjects in the DaySleep and ImmDaySleep conditions were trained in the morning and at noon, respectively, afforded a 90-min nap early in the afternoon and were re-tested 12 h post-training. In the NightSleep condition, subjects were trained in the evening on either of the two learning paradigms and re-tested 12 h later following sleep, while subjects in the NoSleep condition underwent their training session in the morning and were re-tested 12 h later without any intervening sleep. The results of the FTSL task revealed that post-training sleep (day-time nap or night-time sleep) significantly promoted the expression of delayed gains at 12 h post-training, especially if sleep was afforded immediately after training. In the VMA task, however, there were no significant differences in the gains expressed at 12 h post-training in the three conditions. These findings suggest that "off-line" performance gains reflecting consolidation processes in the FTSL task benefit from sleep, even a short nap, while the simple passage of time is as effective as time in sleep for consolidation of VMA to occur. They also imply that procedural memory consolidation processes differ depending on the nature of task demands.
Collapse
Affiliation(s)
- Julien Doyon
- Functional Neuroimaging Unit, University of Montreal Geriatric Institute, 4565 Queen-Mary, Montreal, QC H3W 1W5, Canada.
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Morin A, Doyon J, Dostie V, Barakat M, Tahar AH, Korman M, Benali H, Karni A, Ungerleider LG, Carrier J. Motor sequence learning increases sleep spindles and fast frequencies in post-training sleep. Sleep 2008; 31:1149-56. [PMID: 18714787 PMCID: PMC2542961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023] Open
Abstract
STUDY OBJECTIVES To investigate polysomnographic (PSG) sleep and NREM sleep characteristics, including sleep spindles and spectral activity involved in offline consolidation of a motor sequence learning task. DESIGN Counterbalanced within-subject design. SETTING Three weekly visits to the sleep laboratory. PARTICIPANTS Fourteen healthy participants aged between 20 and 30 years (8 women). INTERVENTIONS Motor sequence learning (MSL) task or motor control (CTRL) task before sleep. MEASUREMENTS AND RESULTS Subjects were trained on either the MSL or CTRL task in the evening and retested 12 hours later the following morning on the same task after a night of PSG sleep recording. Total number and duration of sleep spindles and spectral power between 0.5 and 24 Hz were quantified during NREM sleep. After performing the MSL task, subjects exhibited a large increase in number and duration of sleep spindles compared to after the CTRL task. Higher sigma (sigma; 13 Hz) and beta (beta; 18-20 Hz) spectral power during the post-training night's sleep were also observed after the MSL task. CONCLUSIONS These results provide evidence that sleep spindles are involved in the offline consolidation of a new sequence of finger movements known to be sleep dependent. Moreover, they expand on prior findings by showing that changes in NREM sleep following motor learning are specific to consolidation (and learning), and not to nonspecific motor activity. Finally, these data demonstrate, for the first time, higher fast rhythms (beta frequencies) during sleep after motor learning.
Collapse
Affiliation(s)
- Amélie Morin
- Centre d'éetude du sommeil et des rythmes biologiques, Laboratoire de chronobiologie, Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada
- Functional Neuroimaging Unit, Institut Universitaire de gériatrie de Montréal, Montreal, Quebec, Canada
- Centre de recherche en neuropsychologie et en cognition, Department of Psychology, Université de Montréal, Montreal, Quebec, Canada
| | - Julien Doyon
- Functional Neuroimaging Unit, Institut Universitaire de gériatrie de Montréal, Montreal, Quebec, Canada
- Centre de recherche en neuropsychologie et en cognition, Department of Psychology, Université de Montréal, Montreal, Quebec, Canada
- Unité Mixte de Recherche-S 678, Institut National de la Santé et de la Recherche Médicale/University of Paris 6, Centre Hospitalier Universitaire Pitié-Salp̂etriere, Paris, France
- Laboratory of Brain and Cognition, NIMH, NIH, Bethesda, MD
| | - Valérie Dostie
- Centre d'éetude du sommeil et des rythmes biologiques, Laboratoire de chronobiologie, Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada
- Functional Neuroimaging Unit, Institut Universitaire de gériatrie de Montréal, Montreal, Quebec, Canada
- Centre de recherche en neuropsychologie et en cognition, Department of Psychology, Université de Montréal, Montreal, Quebec, Canada
| | - Marc Barakat
- Functional Neuroimaging Unit, Institut Universitaire de gériatrie de Montréal, Montreal, Quebec, Canada
- Centre de recherche en neuropsychologie et en cognition, Department of Psychology, Université de Montréal, Montreal, Quebec, Canada
| | - Abdallah Hadj Tahar
- Functional Neuroimaging Unit, Institut Universitaire de gériatrie de Montréal, Montreal, Quebec, Canada
- Centre de recherche en neuropsychologie et en cognition, Department of Psychology, Université de Montréal, Montreal, Quebec, Canada
| | - Maria Korman
- Laboratory for Functional Brain Imaging and Learning Research, The Brain-Behavior Center, University of Haifa, Mt Carmel, Israel
| | - Habib Benali
- Functional Neuroimaging Unit, Institut Universitaire de gériatrie de Montréal, Montreal, Quebec, Canada
- Unité Mixte de Recherche-S 678, Institut National de la Santé et de la Recherche Médicale/University of Paris 6, Centre Hospitalier Universitaire Pitié-Salp̂etriere, Paris, France
| | - Avi Karni
- Laboratory for Functional Brain Imaging and Learning Research, The Brain-Behavior Center, University of Haifa, Mt Carmel, Israel
| | | | - Julie Carrier
- Centre d'éetude du sommeil et des rythmes biologiques, Laboratoire de chronobiologie, Hôpital du Sacré-Cœur de Montréal, Montreal, Quebec, Canada
- Functional Neuroimaging Unit, Institut Universitaire de gériatrie de Montréal, Montreal, Quebec, Canada
- Centre de recherche en neuropsychologie et en cognition, Department of Psychology, Université de Montréal, Montreal, Quebec, Canada
| |
Collapse
|
6
|
Samadi P, Grégoire L, Morissette M, Calon F, Tahar AH, Bélanger N, Dridi M, Bédard PJ, Di Paolo T. Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias. Neuropharmacology 2008; 54:258-68. [DOI: 10.1016/j.neuropharm.2007.08.009] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2007] [Revised: 07/31/2007] [Accepted: 08/07/2007] [Indexed: 12/21/2022]
|
7
|
Samadi P, Grégoire L, Morissette M, Calon F, Hadj Tahar A, Dridi M, Belanger N, Meltzer LT, Bédard PJ, Di Paolo T. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging 2007; 29:1040-51. [PMID: 17353071 DOI: 10.1016/j.neurobiolaging.2007.02.005] [Citation(s) in RCA: 100] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2006] [Revised: 01/17/2007] [Accepted: 02/05/2007] [Indexed: 11/22/2022]
Abstract
Modulation of excessive glutamatergic transmission within the basal ganglia is considered as an alternative approach to reduce l-Dopa-induced dyskinesias (LIDs) in Parkinson's disease (PD). In this study receptor binding autoradiography of [3H]MPEP, a metabotropic glutamate receptor 5 (mGluR5) selective radioligand, was used to investigate possible changes in mGluR5 in the basal ganglia of l-Dopa-treated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys having developed LIDs compared to animals in which LIDs was prevented by adjunct treatments. LIDs were associated with an increase of mGluR5 specific binding in the posterior putamen and pallidum (+41% and +56%) compared to controls. By contrast, prevention of dyskinesias was associated with an important decrease of mGluR5 specific binding in these areas (-37% and -48%) compared with dyskinetic animals. Moreover, an upregulation (+34%) of mGluR5 receptor binding was seen in the anterior caudate nucleus of saline treated MPTP monkeys. This study is the first to provide evidence that enhanced mGluR5 specific binding in the posterior putamen and pallidum may contribute to the pathogenesis of LIDs in PD.
Collapse
Affiliation(s)
- Pershia Samadi
- Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre, Quebec, Canada; Faculty of Pharmacy, Laval University, Quebec, Canada
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Samadi P, Morissette M, Calon F, Tahar AH, Dridi M, Belanger N, Meltzer LT, Bédard PJ, Di Paolo T. Normalization of GABAA receptor specific binding in the substantia nigra reticulata and the prevention ofL-dopa-induced dyskinesias in MPTP parkinsonian monkeys. Synapse 2007; 62:101-9. [DOI: 10.1002/syn.20469] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
9
|
Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: Effect on adenosine A2A receptors. Synapse 2006; 60:239-50. [PMID: 16739115 DOI: 10.1002/syn.20295] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Adenosine A(2A) receptors (A(2A)R) have received increasing attention for the treatment of L-DOPA-induced dyskinesias in Parkinson disease. In the present study, A(2A)R messenger RNA (mRNA) and receptor-specific binding in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys were studied after treatment with L-DOPA and a selective NR1A/2B NMDA receptor antagonist, CI-1041. Four MPTP monkeys received L-DOPA/benserazide and all developed dyskinesias, whereas among the four MPTP monkeys who additionally received CI-1041, only one developed mild dyskinesias. Four normal monkeys and four MPTP-treated monkeys were also studied. All MPTP monkeys had similar striatal dopamine (DA) denervation. A(2A)R mRNA levels, measured by in situ hybridization, were increased in the rostral lateral caudate and putamen of saline-treated MPTP monkeys as well as in the caudal lateral and medial putamen when compared with those of controls. A(2A)R mRNA levels remained elevated in the rostral caudate and putamen of L-DOPA-treated MPTP monkeys when compared with those of controls. A(2A)R mRNA levels of L-DOPA + CI-1041-treated monkeys were at control levels and decreased in the lateral rostral caudate and caudal putamen when compared with those of L-DOPA-treated and saline-treated MPTP monkeys respectively. No change was measured in the caudal medial putamen and caudate nucleus. A(2A)Rs labeled by autoradiography with [(3)H]SCH-58261 had lower level in the L-DOPA + CI-1041-treated MPTP monkeys compared with saline- or L-DOPA-treated MPTP and control monkeys in the rostral lateral and medial caudate and the putamen. No effect of lesion or L-DOPA treatment was measured on [(3)H]SCH-58261-specific binding. These findings suggest that blockade of NMDA receptors could prevent the development of dyskinesias by altering A(2A)Rs.
Collapse
Affiliation(s)
- Marc Morissette
- Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre (CHUL), Quebec, Canada
| | | | | | | | | | | | | |
Collapse
|
10
|
Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T. Prevention of levodopa-induced dyskinesias by a selective NR1A/2BN-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin. Mov Disord 2006; 21:9-17. [PMID: 16127720 DOI: 10.1002/mds.20654] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Enkephalin is reported to play an important role in the pathophysiology of levodopa (LD) -induced dyskinesias. The present study investigated the effect of chronic treatment with a selective NR1A/2B N-methyl-D-aspartate (NMDA) receptor antagonist, CI-1041, on the expression of preproenkephalin-A (PPE-A) in brains of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) -treated monkeys in relation to the development of LD-induced dyskinesias. Four MPTP-monkeys received LD/benserazide alone; they all developed dyskinesias. Four other MPTP-monkeys received LD/benserazide plus CI-1041; only one of them developed mild dyskinesias at the end of the fourth week of treatment. Four normal monkeys and four saline-treated MPTP monkeys were also included. MPTP-treated monkeys had extensive and similar striatal dopamine denervation. An increase of PPE-A mRNA levels assayed by in situ hybridization was observed in the lateral putamen (rostral and caudal) and caudate nucleus (rostral) of saline-treated MPTP monkeys compared to controls, whereas no change or a small increase was observed in their medial parts. Striatal PPE-A mRNA levels remained elevated in LD-treated MPTP monkeys, whereas cotreatment with CI-1041 brought them back to control values. These findings suggest that chronic blockade of striatal NR1A/2B NMDA receptors with CI-1041 normalizes PPE-A mRNA expression and prevents the development of LD-induced dyskinesias in an animal model of Parkinson disease.
Collapse
Affiliation(s)
- Marc Morissette
- Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre, Quebec, Canada
| | | | | | | | | | | | | |
Collapse
|
11
|
Samadi P, Grégoire L, Hadj Tahar A, Di Paolo T, Rouillard C, Bédard PJ. Naltrexone in the short-term decreases antiparkinsonian response to -Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys. Neuropharmacology 2005; 49:165-73. [PMID: 15996565 DOI: 10.1016/j.neuropharm.2005.02.009] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2004] [Revised: 01/27/2005] [Accepted: 02/11/2005] [Indexed: 11/27/2022]
Abstract
Nigrostriatal dopaminergic denervation and levodopa therapy in animal models and in parkinsonian patients are associated with an enhanced opioid transmission in the striatum. The functional role of this increase has always been a subject of debate. In this study two groups of drug-naïve macaque monkeys with MPTP-induced parkinsonism were treated daily, during four weeks, with l-Dopa alone or l-Dopa plus naltrexone, a non-selective opioid receptor antagonist. The improvement of parkinsonism in all animals treated with l-Dopa alone was clearly displayed from the first day of treatment. By contrast, naltrexone co-treatment blocked the antiparkinsonian action of l-Dopa for 7-14 days. As soon as the therapeutical action of l-Dopa appeared in naltrexone-treated monkeys, the magnitude and duration of the antiparkinsonian response were similar in both groups. Furthermore, in animals treated with l-Dopa plus naltrexone the beginning of the therapeutical effect of l-Dopa was accompanied by the appearance of dyskinesias. In this group, the severity of dyskinesias during the third and fourth weeks of treatment was significantly higher than the group treated with l-Dopa alone. The results of the present study demonstrate that in de novo MPTP parkinsonian monkeys antagonizing the action of opioid receptors worsens the motor response to l-Dopa.
Collapse
Affiliation(s)
- Pershia Samadi
- Centre de recherche en Neurosciences, CHUL Sainte-Foy, Québec, Canada
| | | | | | | | | | | |
Collapse
|
12
|
Blanchet PJ, Calon F, Morissette M, Hadj Tahar A, Bélanger N, Samadi P, Grondin R, Grégoire L, Meltzer L, Di Paolo T, Bédard PJ. Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism Relat Disord 2004; 10:297-304. [PMID: 15196509 DOI: 10.1016/j.parkreldis.2004.02.011] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2004] [Accepted: 02/23/2004] [Indexed: 10/26/2022]
Abstract
For nearly 20 years, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model has allowed great strides to be made in our understanding of the maladaptive changes underlying the levodopa-related motor response complications occurring in most parkinsonian patients. Studies indicate that sustained dopamine D2 receptor occupancy can prevent and reverse existing dyskinesias. Recent experiments in levodopa-treated MPTP animals, co-administered either a threshold dose of cabergoline or a glutamate NMDA NR2B-selective antagonist (CI-1041), have afforded protection against dyskinesia, perhaps through presynaptic inhibition of glutamate release and blockade of supersensitive postsynaptic NMDA receptors in the striatum, respectively. Some of the biochemical events that have correlated with dyskinesias, namely upregulated GABA(A) receptors in the internal pallidum, rise in pre-proenkephalin-A gene expression in the striatum, and upregulated striatal glutamate ionotropic receptors and adenosine A(2a) receptors, may be counteracted by these preventive strategies.
Collapse
Affiliation(s)
- Pierre J Blanchet
- Department of Stomatology, Faculty of Dental Medicine, University of Montreal, Que., Canada
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Hadj Tahar A, Grégoire L, Darré A, Bélanger N, Meltzer L, Bédard PJ. Effect of a selective glutamate antagonist on l-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol Dis 2004; 15:171-6. [PMID: 15006686 DOI: 10.1016/j.nbd.2003.10.007] [Citation(s) in RCA: 115] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2003] [Revised: 10/16/2003] [Accepted: 10/22/2003] [Indexed: 11/18/2022] Open
Abstract
Alterations of striatal glutamate receptors are believed to be responsible, at least in part, for the pathogenesis of L-dopa-induced dyskinesias (LID). To evaluate whether co-administration of CI-1041, a novel NMDA receptor antagonist selective for the NR1A/NR2B subtype, with L-dopa might prevent the appearance of this side effect, eight de novo parkinsonian monkeys were treated chronically orally with either L-dopa alone or L-dopa plus CI-1041 (n= 4 for each group). After 4 weeks of treatment with L-dopa alone, all four animals developed moderate dyskinesias either choreic or dystonic in nature. CI-1041 co-treatment completely prevented the induction of dyskinesias in three animals and only one monkey developed mild dyskinesias at the end of the fourth week of treatment in the L-dopa + CI-1041 group. The magnitude and duration of the antiparkinsonian action of L-dopa was similar in both groups. These results suggest that selective NMDA receptor antagonism may be interesting for managing LID in Parkinson's disease patients.
Collapse
Affiliation(s)
- Abdallah Hadj Tahar
- Neuroscience Research Unit (RC 9800), CHUL, Laval University Research Center, Ste-Foy, Québec, Canada G1V 4G2
| | | | | | | | | | | |
Collapse
|
14
|
Abstract
NMDA receptor antagonists impair learning and memory in animal models, presumably by inhibiting long-term potentiation in the motor cortex. Human studies are limited and restricted by the paucity of safe NMDA antagonists. Here, we investigated the contribution of glutamatergic neurotransmission to the capacity of acquiring motor-adaptation learning in humans. In a double-blind design, 200 mg of amantadine (a low-affinity NMDA receptor channel blocker) or a matching placebo were given orally to groups of 14 and 13 human healthy young volunteers, respectively. Blood samples were collected 3 h after treatment to assay plasma concentrations, and the subjects were then tested using a motor-adaptation paradigm consisting of an eight-target-pointing task. To rule out drug-related generalized impairments such sedation, tests measuring motor dexterity and attention were also administered pre- and post-treatment. Comparison of the mean performance levels on the motor-adaptation task revealed that subjects in the amantadine group performed at a lower level than those in the placebo group, but this difference did not reach significance. Interestingly, however, despite plasma amantadine concentrations being relatively low, ranging from 2.09 to 4.74 microM (mean=3.3 microM), they nevertheless correlated negatively with motor learning. Furthermore, when the amantadine group was divided into low-performance and high-performance subgroups, subjects in the former subgroup displayed mean amantadine concentrations 36% higher than the latter subgroup, and performed significantly worser than the placebo group. No change in performance was found on the motor-dexterity and attention tests. Altogether, our results lend support to the hypothesis that normal NMDA receptor function is necessary for the acquisition of motor adaptation.
Collapse
Affiliation(s)
- Abdallah Hadj Tahar
- Department of Psychology, University of Montreal, Downtown, Montreal, Que, Canada.
| | | | | |
Collapse
|
15
|
Bélanger N, Grégoire L, Hadj Tahar A, Bédard PJ. Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 2003; 18:1436-41. [PMID: 14673879 DOI: 10.1002/mds.10589] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
Levodopa continues to be the most effective agent for the symptomatic treatment of Parkinson's disease (PD). But over time, initial benefits decline in efficacy because of a rise in adverse effects such as dyskinesias. The pathophysiology of levodopa-induced dyskinesias (LID) is not completely understood, but it appears to result from deficient regulation by dopamine of corticostriatal glutamatergic inputs leading to a cascade of neurochemical changes in the striatum and the output pathways. In the present study, we examined if the addition of small doses of cabergoline (a long-acting D(2) receptor agonist) to levodopa could prevent LID. The major hypothesis is that sustained activation of postsynaptic D(2) receptors on medium spiny neurons even by small doses of cabergoline could prevent or reduce LID. The minor hypothesis, and the more controversial of the two, is that the long-acting stimulation by small doses of cabergoline could diminish the release of glutamate by the corticostriatal pathway and prevent LID. Eight MPTP-treated monkeys with a long-standing and stable parkinsonian syndrome and having never received dopaminergic agents were used. Two groups of four were treated for 1 month with levodopa/benserazide administered orally (100 mg/25 mg). The second group received in addition a threshold dose of cabergoline (dose ranging from 0.015 to 0.035 mg/kg, SC). During the treatment, we observed LID in the levodopa group but not in the group receiving levodopa+cabergoline. Furthermore, the combination produced a comparable antiparkinsonian effect in terms of quality but prolonged the duration (by 1 to 2 hours) and increased the locomotion (mean for 2 weeks congruent with 104%). Our data suggest that a small dose of a long-acting D(2) agonist combined with high doses of levodopa could be preventive of LID in patients with PD and could be an alternative to using antiglutamatergic agents for this purpose.
Collapse
Affiliation(s)
- Nancy Bélanger
- Department of Medicine and Neuroscience Unit, Laval University and Research Center, Ste-Foy, Quebec, Canada
| | | | | | | |
Collapse
|